文献速递关节外科创伤骨科

全髋关节置换术后预防性抗凝下的肺栓塞发生率:部分肺栓塞无法避免

Pulmonary Embolism Rates Following Total Hip Arthroplasty With Prophylactic Anticoagulation: Some Pulmonary Emboli Cannot Be Avoided.
PubMed 文献 · J Arthroplasty · 2016-09-28

该研究检索1995年1月至2015年12月的随机对照试验,评估全髋关节置换术(THA)患者预防性抗凝下的症状性肺栓塞(PE)发生率,共纳入21项研究、34,764例患者。汇总估计PE发生率为0.21%(95%CI:0.13%,0.32%),1997年至2013年间回归分析显示PE比例无变化。作者认为即使健康THA患者接受积极抗凝仍存在PE风险,「never event」的 designation 需要重新评估。

要点

  • 21项随机对照试验共34,764例全髋关节置换术患者,汇总症状性肺栓塞估计发生率为0.21%(95%CI:0.13%,0.32%)。
  • 1997年至2013年间回归分析显示肺栓塞比例无变化。
  • 作者认为即使健康全髋关节置换术患者接受积极抗凝仍存在肺栓塞风险,「never event」 designation 需要重新评估。

核心结论

  • 全髋关节置换术后肺栓塞发生率虽低,但在跨越17年的随机对照试验中保持一致,这些试验排除了有显著合并症的患者。
  • 作者认为即使健康的全髋关节置换术患者接受积极抗凝仍存在肺栓塞风险,「never event」的 designation 需要重新评估。

研究设计与样本

  • 检索MEDLINE和Cochrane Central Register of Controlled Trials,纳入1995年1月至2015年12月评估全髋关节置换术患者预防性抗凝的随机对照试验。
  • 共纳入21项研究、34,764例患者,使用随机效应模型合并各研究的肺栓塞发生率。

主要发现

  • 21项研究共34,764例患者,汇总估计肺栓塞发生率为0.21%(95%CI:0.13%,0.32%)。
  • 患者接受的药物包括低分子量肝素(13,590例)、口服Xa因子抑制剂(6,609例)、口服直接凝血酶抑制剂(5,965例)、间接Xa/IIa因子抑制剂(3,444例)、阿司匹林(2,427例)和华法林(489例)。
  • 使用移动加压装置者199例,使用安慰剂者2,041例。
  • 1997年至2013年间,回归分析显示肺栓塞比例无变化。

局限性

  • 这些随机对照试验排除了有显著合并症的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A symptomatic pulmonary embolism (PE) after total joint arthroplasty has been described as a "never event." Despite potent anticoagulants and improvements in patient care, PE continues to occur following total hip arthroplasty (THA). This study evaluates symptomatic PE rates over time in THA patients enrolled in multicenter randomized clinical trials (RCTs) assessing the efficacy of venous thromboembolism prophylaxis regimens. METHODS: The MEDLINE and Cochrane Central Register of Controlled Trials were searched to identify clinical trials assessing prophylactic anticoagulation in patients undergoing THA between January 1995 and December 2015. Inclusion criteria consisted of RCTs evaluating prophylactic anticoagulation in patients undergoing THA. A random effect model was used to combine PE rates across studies. RESULTS: A total of 21 studies (34,764 patients) were included. Patients were administered low molecular weight heparin (13,590 patients), oral factor Xa inhibitors (6609 patients), oral direct thrombin inhibitors (5965 patients), indirect factors Xa/IIa inhibitors (3444 patients), aspirin (2427 patients), and warfarin (489 patients). Mobile compression was used in 199 patients, and placebo was used in 2041 patients. Across all included studies, the estimated PE rate was 0.21% (95% confidence interval: 0.13%, 0.32%). Between 1997 and 2013, the proportion of PEs did not change in regression analysis. CONCLUSION: Although the PE rate was low, it was consistent throughout the 17 years spanning these RCTs, which excluded patients with significant morbidity. These results suggest that even healthy THA patients receiving aggressive anticoagulation still have a risk for PE, and the "never event" designation requires reassessment.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Lieberman JR, Cheng V, Cote MP, et al. Pulmonary Embolism Rates Following Total Hip Arthroplasty With Prophylactic Anticoagulation: Some Pulmonary Emboli Cannot Be Avoided. J Arthroplasty. 2016. PMID: 27866948. doi:10.1016/j.arth.2016.09.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。